[Cardiac protection as priority strategy of cardiovascular prevention in high blood pressure]

V Barrios Alonso1, A Calderón Montero, C Escobar Cervantes

  • 1Instituto de Cardiología, Hospital Ramón y Cajal, Madrid. vbarrios.hrc@salud.madrid.org

Revista Clinica Espanola
|October 1, 2005
PubMed

Insights

Cardiac complications remain a major cause of death and illness from high blood pressure (HBP). Protecting the heart is a priority for managing HBP and preventing serious health issues.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Public Health

Context:

  • Cardiac complications are the leading cause of morbidity and mortality associated with high blood pressure (HBP).
  • Despite decreased incidence of cerebrovascular accidents (ACVA), cardiac complications persist due to multifactorial origins.
  • Left ventricular hypertrophy is a key factor in hypertensive heart disease, encompassing heart failure, ischemic heart disease, arrhythmias, and sudden death.

Purpose:

  • To highlight the significant burden of cardiac complications in high blood pressure (HBP) management.
  • To emphasize the persistent challenge of cardiac issues despite advances in stroke prevention.
  • To underscore the critical role of cardiac protection in addressing HBP-related morbidity and mortality.

Summary:

  • High blood pressure (HBP) significantly contributes to cardiac morbidity and mortality.
  • Left ventricular hypertrophy is central to hypertensive heart disease, leading to various cardiac conditions.
  • Cardiac complications, including heart failure and arrhythmias, represent a major health concern in HBP patients.

Impact:

  • Cardiac protection strategies are crucial for improving outcomes in high blood pressure (HBP) patients.
  • Addressing cardiac complications is essential for reducing the overall burden of HBP.
  • Prioritizing cardiac health in HBP management can mitigate severe human and socio-economic consequences.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...